Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Pancreatic cancer
Trial Type:  Treatment
Results 1-25 of 177 for your search:
Start Over
Preoperative Biliary Drainage in Resectable Pancreatic or Periampullary Cancer
Status: Active
Phase: Phase IV
Type: Treatment
Age: 18 and over
Trial IDs: CDM00047339, NCI-2016-00348, E7059, NCT01774019
Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery
Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: RTOG 0848, NCI-2011-01987, CDR0000659092, NCT01013649
Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)
Status: Active
Phase: Phase III, Phase II
Type: Treatment
Age: 18 and over
Trial IDs: PCYC-1137-CA, NCI-2015-01722, NCT02436668
Surgery With or Without Intraperitoneal Drainage in Improving Complication Rate in Patients With Pancreatic Disease
Status: Active
Phase: Phase III
Type: Health services research, Treatment
Age: 18 and over
Trial IDs: H-28324, NCI-2012-01881, NCT01441492
Combination Chemotherapy with or without Stereotactic Body Radiation Therapy in Treating Patients with Locally Advanced Pancreatic Cancer
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: Over 18
Trial IDs: PANC0015, NCI-2013-01658, 5136, NCT01926197
Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: EP-GF-301, NCI-2013-02181, NCT01954992
Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: D081FC00001, NCI-2015-00038, 2014-001589-85, NCT02184195
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BBI608-201, NCI-2014-01566, NCT01325441
Stereotactic Body Radiation Therapy in Treating Patients with Pancreatic or Ampulla of Vater Cancer That Cannot Be Removed by Surgery
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 16866B, NCI-2015-01656, NCT01342354
A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CMEK162X2109, NCI-2012-00874, 2011-002578-21, NCT01449058
Veliparib and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2009-608, NCI-2013-00656, NCT01489865
A Phase I/II/Pharmacodynamic Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane to Inhibit Autophagy in Pancreatic Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UPCC 19211, NCI-2012-00026, NCT01506973
Genetically Engineered Lymphocytes in Treating Patients with Metastatic Cancer or Cancer That Cannot Be Removed by Surgery Receiving Chemotherapy and Aldesleukin
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 66
Trial IDs: 12-C-0111, NCI-2013-01516, 1112-1139, 120111, P11928, RD-12-I-02, NCT01583686
M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 65
Trial IDs: M402-103, NCI-2012-02125, NCT01621243
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: IM-T-IMMU-132-01, NCI-2014-00136, NCT01631552
Probiotic LGG for Prevention of Side Effects in Patients Undergoing Chemoradiation for Gastrointestinal Cancer
Status: Active
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: 201404101, NCI-2013-00650, NCT01790035
A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CA209-032, NCI-2013-02337, 2013-002844-10, NCT01928394
S1313, Combination Chemotherapy with or without PEGPH20 in Treating Patients with Newly Diagnosed Metastatic Pancreatic Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: S1313, NCI-2013-01776, PS1313_A09PAMDREVW01, NCT01959139
Talazoparib in Treating Patients with Advanced Solid Tumors and BRCA Mutations
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9510, NCI-2013-02371, 09-25-0099, 140015, P131220, P9510_A08PAMDREVW01, 14-C-0015, NCT01989546
Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NLG2104, NCI-2014-02095, NCT02077881
Trametinib and Navitoclax in Treating Patients with Advanced or Metastatic Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-505, NCI-2014-00461, 9525, NCT02079740
Selinexor, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients with Metastatic Pancreatic Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: 2013-133, NCI-2014-01249, 1403012942, NCT02178436
A Phase 1/2 Trial of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 as Neoadjuvant Chemotherapy in Locally Advanced, Unresectable Pancreatic Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: FGCL-3019-069, NCI-2015-01207, NCT02210559
Multi-tracer PET/CT in Predicting and Assessing Response in Patients with Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer Receiving Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Diagnostic, Treatment
Age: 18 and over
Trial IDs: HCI74163, NCI-2014-02370, 74163, NCI-2014-02286, NCT02245217
Start Over